Anti-Glomerular Basement Membrane Disease Mechanisms and Clinical Outcomes

Anti-glomerular basement membrane (anti-GBM) disease is an uncommon but aggressive autoimmune disorder characterised by circulating autoantibodies targeting the non-collagenous domain of the α3 chain of type IV collagen in glomerular and alveolar basement membranes. Binding of these antibodies triggers complement activation, recruitment of inflammatory cells and rapid development of crescentic glomerulonephritis, often accompanied by pulmonary haemorrhage. Genetic predisposition, particularly specific HLA alleles, and environmental factors such as tobacco smoke or hydrocarbon exposure contribute to loss of self-tolerance. Histologically, patients present with linear immunoglobulin deposition along the basement membrane and widespread crescent formation in Bowman’s spaces. Clinically, the spectrum ranges from fulminant renal failure requiring dialysis to isolated pulmonary involvement. Early aggressive management—combining plasmapheresis to remove pathogenic antibodies with immunosuppressive agents such as cyclophosphamide, corticosteroids or B-cell depletion therapies—has improved patient survival, but long-term renal outcome remains variable. Prognostic indicators include serum creatinine at presentation, degree of crescent formation on biopsy and patterns of complement deposition. Emerging evidence around atypical presentations, coexistence with antineutrophil cytoplasmic antibodies and novel biomarkers promises refined risk stratification and personalised treatment pathways.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Anti-Glomerular Basement Membrane Disease Mechanisms and Clinical Outcomes publication trend

The graph below shows the total number of articles in anti-glomerular basement membrane disease mechanisms and clinical outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Anti-GBM antibodies: Autoantibodies directed against the non-collagenous domain of the α3 chain of type IV collagen in glomerular and alveolar basement membranes.

Complement C3: A central component of the complement cascade whose activation and deposition amplify inflammatory damage in glomeruli.

Crescentic glomerulonephritis: A severe form of glomerular injury marked by proliferation of epithelial cells and macrophages in Bowman’s space, forming crescents.

Atypical anti-GBM disease: A variant characterised by linear tissue deposition of IgG in the absence of detectable circulating anti-GBM antibodies using standard assays.

Double-positive disease: Coexistence of anti-GBM antibodies and antineutrophil cytoplasmic antibodies, producing overlapping features of vasculitis and anti-GBM injury.

Plasmapheresis: An extracorporeal procedure that removes circulating autoantibodies and immune complexes to mitigate ongoing tissue damage.

References

1. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease. Frontiers in Immunology (2023).
2. Atypical Anti-Glomerular Basement Membrane Disease. Kidney International Reports (2023).
3. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney International (2017).
4. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV.. Journal of Biological Chemistry (1988).
5. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Frontiers in Immunology (2019).